AZoLifeSciences on MSN
Genetic differences can undermine antibody-based therapies
The genome differs from person to person in thousands of positions. In some cases, this means that proteins have a different ...
Rezolute, Inc. is downgraded to a Sell after its phase 3 sunRIZE trial for congenital hyperinsulinism failed. Learn more ...
The European Union has adopted a centralised, horizontal approach to AI regulation through the EU AI Act, the world’s first ...
AI initiatives don’t stall because models aren’t good enough, but because data architecture lags the requirements of agentic systems.
The genome differs from person to person in thousands of positions. In some cases, this means that proteins have a different building block in certain regions, rendering some antibody-based therapies ...
Antibody-based therapies are used to treat numerous diseases, from cancer to rheumatic disorders and multiple sclerosis.
Researchers in the Nanoscience Center at the University of Jyväskylä, Finland, have developed a pioneering computational ...
Researchers are striving to understand the impact a phenomenon known as original antigenic sin has on immunity to the virus.
How AI, privacy-preserving computation, and explainable models quietly strengthen payments, protect data, and bridge traditional finance with crypto systems.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results